poisar

Stocks · News reference

Formycon Identifies Reference Products for Biosimilar Candidates FYB210 and FYB286

Fiscal.ai

Formycon AG has officially named the reference drugs for its pipeline candidates FYB210 and FYB286, identifying them as Tezspire (tezepelumab) and Hemlibra (emicizumab), respectively.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading